Eisai looks to cost competitiveness and Asia as it refocuses post-Aricept business
This article was originally published in Scrip
Executive Summary
With US revenues from its former mainstay product a shadow of what they were at this time last year, Eisai chose to focus on its affordable medicines initiatives, geographical business shift and innovative skills at an annual corporate briefing in Tokyo.